Cargando…
In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice
Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-co...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457798/ https://www.ncbi.nlm.nih.gov/pubmed/36080307 http://dx.doi.org/10.3390/molecules27175540 |
_version_ | 1784786144662126592 |
---|---|
author | Bhat, Zahid Rafiq Kumar, Manvendra Sharma, Nisha Yadav, Umesh Prasad Singh, Tashvinder Joshi, Gaurav Pujala, Brahmam Raja, Mohd Chatterjee, Joydeep Tikoo, Kulbhushan Singh, Sandeep Kumar, Raj |
author_facet | Bhat, Zahid Rafiq Kumar, Manvendra Sharma, Nisha Yadav, Umesh Prasad Singh, Tashvinder Joshi, Gaurav Pujala, Brahmam Raja, Mohd Chatterjee, Joydeep Tikoo, Kulbhushan Singh, Sandeep Kumar, Raj |
author_sort | Bhat, Zahid Rafiq |
collection | PubMed |
description | Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-covalent imidazo[1,2-a]quinoxaline-based EGFR inhibitor (6b), which showed promising inhibitory activity against the gefitinib-resistant H1975(L858R/T790M) lung cancer cell line. In the present study, we further explored the 6b compound in vivo by employing the A549-induced xenograft model in nude mice. The results indicate that the administration of the 6b compound significantly abolished the growth of the tumor in the A549 xenograft nude mice. Whereas the control mice bearing tumors displayed a declining trend in the survival curve, treatment with the 6b compound improved the survival profile of mice. Moreover, the histological examination showed the cancer cell cytotoxicity of the 6b compound was characterized by cytoplasmic destruction observed in the stained section of the tumor tissues of treated mice. The immunoblotting and qPCR results further signified that 6b inhibited EGFR in tissue samples and consequently altered the downstream pathways mediated by EGFR, leading to a reduction in cancer growth. Therefore, the in vivo findings were in corroboration with the in vitro results, suggesting that 6b possessed potential anticancer activity against EGFR-dependent lung cancer. 6b also exhibited good stability in human and mouse liver microsomes. |
format | Online Article Text |
id | pubmed-9457798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94577982022-09-09 In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice Bhat, Zahid Rafiq Kumar, Manvendra Sharma, Nisha Yadav, Umesh Prasad Singh, Tashvinder Joshi, Gaurav Pujala, Brahmam Raja, Mohd Chatterjee, Joydeep Tikoo, Kulbhushan Singh, Sandeep Kumar, Raj Molecules Article Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-covalent imidazo[1,2-a]quinoxaline-based EGFR inhibitor (6b), which showed promising inhibitory activity against the gefitinib-resistant H1975(L858R/T790M) lung cancer cell line. In the present study, we further explored the 6b compound in vivo by employing the A549-induced xenograft model in nude mice. The results indicate that the administration of the 6b compound significantly abolished the growth of the tumor in the A549 xenograft nude mice. Whereas the control mice bearing tumors displayed a declining trend in the survival curve, treatment with the 6b compound improved the survival profile of mice. Moreover, the histological examination showed the cancer cell cytotoxicity of the 6b compound was characterized by cytoplasmic destruction observed in the stained section of the tumor tissues of treated mice. The immunoblotting and qPCR results further signified that 6b inhibited EGFR in tissue samples and consequently altered the downstream pathways mediated by EGFR, leading to a reduction in cancer growth. Therefore, the in vivo findings were in corroboration with the in vitro results, suggesting that 6b possessed potential anticancer activity against EGFR-dependent lung cancer. 6b also exhibited good stability in human and mouse liver microsomes. MDPI 2022-08-28 /pmc/articles/PMC9457798/ /pubmed/36080307 http://dx.doi.org/10.3390/molecules27175540 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bhat, Zahid Rafiq Kumar, Manvendra Sharma, Nisha Yadav, Umesh Prasad Singh, Tashvinder Joshi, Gaurav Pujala, Brahmam Raja, Mohd Chatterjee, Joydeep Tikoo, Kulbhushan Singh, Sandeep Kumar, Raj In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice |
title | In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice |
title_full | In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice |
title_fullStr | In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice |
title_full_unstemmed | In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice |
title_short | In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice |
title_sort | in vivo anticancer evaluation of 6b, a non-covalent imidazo[1,2-a]quinoxaline-based epidermal growth factor receptor inhibitor against human xenograft tumor in nude mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457798/ https://www.ncbi.nlm.nih.gov/pubmed/36080307 http://dx.doi.org/10.3390/molecules27175540 |
work_keys_str_mv | AT bhatzahidrafiq invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT kumarmanvendra invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT sharmanisha invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT yadavumeshprasad invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT singhtashvinder invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT joshigaurav invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT pujalabrahmam invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT rajamohd invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT chatterjeejoydeep invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT tikookulbhushan invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT singhsandeep invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice AT kumarraj invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice |